{"schema_version":"secwatch.filing_event.v1","accession":"0001178670-25-000089","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.498634+00:00","generated_at":"2026-05-17T22:10:37.646212+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alnylam Q2 net product rev $672M (+64% YoY); TTR franchise $544M (+77%); raises FY guidance","bullets":["Q2 net product revenues $672M, +64% YoY; TTR franchise $544M (+77%) driven by AMVUTTRA sales of $492M.","GAAP loss from operations $16M vs income $49M in Q2 2024; non-GAAP income from operations $95M.","Raised FY2025 guidance: TTR revenue to $2.175-2.275B; total net product revenue to $2.65-2.8B (+27% at midpoint).","~1,400 ATTR-CM patients on AMVUTTRA as of June 30; approvals secured in EU, UK, Brazil, and Japan.","Initiated TRITON-CM Phase 3 trial for nucresiran in ATTR-CM; received FDA Fast Track designation."],"urls":{"canonical":"https://secwatch.observer/filing/0001178670-25-000089","json":"https://secwatch.observer/filing/0001178670-25-000089.json","markdown":"https://secwatch.observer/filing/0001178670-25-000089.md","text":"https://secwatch.observer/filing/0001178670-25-000089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000117867025000089/0001178670-25-000089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000117867025000089/alny-20250731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:10:37.646212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}